RSV prophylactics for pediatric populations: A product review and meta-analysis of real-world effectiveness.

Hum Vaccin ImmunotherJun 25, 2026 (epub)
Clinical ResearchPediatricsOpen access

Isabela O Oliva, Carlos R Oliveira

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis reviewed the real-world effectiveness of RSV prophylactics in pediatric populations, focusing on nirsevimab and maternal RSVpreF vaccination. The study found that nirsevimab had an 80.9% effectiveness against RSV-associated hospitalization, while maternal vaccination showed 79.1% effectiveness. The analysis included data from 43 observational studies.

Key findings

  • Nirsevimab demonstrated an 80.9% effectiveness against RSV-associated hospitalization.
  • Maternal RSVpreF vaccination showed a 79.1% effectiveness in preventing RSV-related hospitalizations.
  • The review emphasizes the importance of equitable access to these prophylactic strategies.

Why it matters

Understanding the effectiveness of new RSV prophylactics is crucial for clinicians managing pediatric patients, particularly in high-risk groups. These findings can inform clinical decisions and public health strategies to reduce RSV-related morbidity.

Source

Published in Hum Vaccin Immunother. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.